Riptam

Riptam may be available in the countries listed below.

Ingredient matches for Riptam

Mitomycin

Mitomycin is reported as an ingredient of Riptam in the following countries:

• Peru

Oxaliplatin

Oxaliplatin is reported as an ingredient of Riptam in the following countries:

• Mexico

International Drug Name Search

Mitilase

Mitilase may be available in the countries listed below.

Ingredient matches for Mitilase

Fluoxetine

Fluoxetine hydrochloride (a derivative of Fluoxetine) is reported as an ingredient of Mitilase in the following countries:

• Argentina

International Drug Name Search

Saiflu

Saiflu may be available in the countries listed below.

Ingredient matches for Saiflu

Oseltamivir

Oseltamivir phosphate (a derivative of Oseltamivir) is reported as an ingredient of Saiflu in the following countries:

• Algeria

International Drug Name Search

Pristiq

Pristiq is a brand name of desvenlafaxine, approved by the FDA in the following formulation(s):

PRISTIQ (desvenlafaxine succinate - tablet, extended release; oral)

• 
  Manufacturer: WYETH PHARMS INC
  
  Approval date: February 29, 2008
  
  Strength(s): EQ 100MG BASE ^[RLD], EQ 50MG BASE ^[RLD]

Has a generic version of Pristiq been approved?

No. There is currently no therapeutically equivalent version of Pristiq available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Pristiq. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Succinate salt of O-desmethyl-venlafaxine
  Patent 6,673,838
  Issued: January 6, 2004
  Inventor(s): Anthony F.; Hadfield & Syed M.; Shah & Michael W.; Winkley & Karen W.; Sutherland & James A.; Provost & Aeri; Park & Rex A.; Shipplett & Brenton W.; Russell & Beat T.; Weber
  Assignee(s): Wyeth
  A novel salt of O-desmethyl venlafaxine is provided, O-desmethylvenlafaxine succinate. Pharmaceutical compositions, dosage forms and methods of use are also provided.
  
  Patent expiration dates:
  
  
  • February 11, 2022
    
    ✓ 
    Patent use: FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • March 1, 2013 - NEW CHEMICAL ENTITY
  
  

See also...

• Pristiq Consumer Information (Drugs.com)
• Pristiq Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Pristiq Consumer Information (Cerner Multum)
• Pristiq Advanced Consumer Information (Micromedex)
• Pristiq AHFS DI Monographs (ASHP)
• Desvenlafaxine Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Desvenlafaxine Consumer Information (Cerner Multum)
• Desvenlafaxine Advanced Consumer Information (Micromedex)
• Desvenlafaxine Succinate AHFS DI Monographs (ASHP)

Sancap

Sancap may be available in the countries listed below.

Ingredient matches for Sancap

Captopril

Captopril is reported as an ingredient of Sancap in the following countries:

• Greece

International Drug Name Search

Eupantol

Eupantol may be available in the countries listed below.

Ingredient matches for Eupantol

Pantoprazole

Pantoprazole sodium (a derivative of Pantoprazole) is reported as an ingredient of Eupantol in the following countries:

• France

International Drug Name Search